Mankind Pharma Q1 FY27 profit rises 29.6% to ₹568 crore as revenue grows 12.9%
Mankind Pharma reported Q1 FY27 revenue from operations of ₹4,030.6 crore and a 14.1% net margin, helped by a 35.6% fall in finance costs. Its board also approved a corporate guarantee of up to ₹150 crore for Bharat Serums and Vaccines and a ₹49 crore sale of its Broadway Hospitality stake.
What happened
Mankind Pharma’s Q1 FY27 net profit rose 29.6% to ₹568.06 crore as revenue grew 12.9% and finance costs fell. The board approved a ₹150 crore guarantee for
Key facts
- Q1 FY27 net profit ₹568.06 crore, up 29.6% YoY
- Revenue from operations ₹4,030.59 crore, up 12.9% YoY
- Total income ₹4,075.59 crore, up 11.7% YoY
- Total expenses ₹3,310.08 crore, up 6.3% YoY
- Finance costs ₹109.98 crore, down 35.6% YoY
- Profit before tax ₹769.45 crore, up 42.4% YoY
- Net profit margin 14.1%, versus 12.3%
- Corporate guarantee up to ₹150 crore for Bharat Serums and Vaccines
- Broadway Hospitality stake sale for ₹49 crore
- Income-tax assessment adjustments ₹1,908.66 crore
Why this matters
The ₹150 crore corporate guarantee for Bharat Serums and Vaccines reinforces Mankind’s backing of its acquired business, while the ₹49 crore Broadway Hospitality stake sale modestly streamlines non-core holdings.
What to watch
- Whether finance costs remain materially below prior-year levels in the next two quarters.
- BSV's funding requirements, corporate-guarantee drawdown and any resulting change in consolidated leverage.
- Growth in chronic, specialty and hospital-facing therapies relative to the core acute portfolio.
- Gross-margin movement, field-force and marketing expense growth, and EBITDA-margin sustainability.
- Regulatory pricing actions, tender exposure and competitive intensity in key therapeutic categories.
- Timing and use of cash from the ₹49 crore Broadway Hospitality stake sale.
- Prioritize cross-selling of BSV products through Mankind's physician and hospital relationships while protecting specialty-brand pricing.
- Use improved cash flows to reduce expensive debt or refinance acquisition-linked borrowings before increasing discretionary spending.
- Deploy proceeds from the Broadway Hospitality stake sale toward core pharma operations, debt reduction or BSV integration rather than non-core investments.
- Increase disclosure on BSV revenue, EBITDA contribution, synergy realization, leverage and guarantee utilization to support investor confidence.